In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

This was the stock's second consecutive day of gains.

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...